The Journal of Pediatrics
Volume 155, Issue 4, Supplement , Pages S19-S31 , October 2009

Guidelines to Diagnosis and Monitoring of Fabry Disease and Review of Treatment Experiences

References 

  1. Desnick R, Ioannou Y, Eng C. Alpha-Galactosidase A deficiency: Fabry disease. In:  Scriver CR BA,  Sly WS,  Valle D editor. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001;p. 3733–3774
  2. Deegan PB, Baehner AF. Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006;43:347–352
  3. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007;9:34–45
  4. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112–128
  5. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–807
  6. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254
  7. Anderson W. A case of “angiokeratoma”. Br J Dermatol. 1898;10:113–117
  8. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphilis. 1898;43:187–200
  9. Pompen A, Ruiter M, Wyers H. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease: two autopsy reports. Acta Med Scand. 1947;128:234–255
  10. Scriba K. Zur Diagnostik des Angiokeratoma corporis diffusum Fabry mit cardio-vasorenalem Symptomenkomplex. Verh Dtsch Ges Pathol. 1950;34:221
  11. Hornbostel H, Scriba K. Zur Diagnostik des Angiokeratoma corporis diffusum Fabry mit cardio-vasorenalem Symptomenkomplex als posphatidspeicherungskrankheit durch Probeexcision der Haut. Klin Wochenschr. 1953;31:68
  12. Sweeley C, Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem. 1963;238:3148–3150
  13. Hers H. Inborn lysosomal diseases. Gastroenterology. 1965;48:625–633
  14. Brady RO. Enzymatic abnormalities in diseases of sphingolipid metabolism. Clin Chem. 1967;13:565–577
  15. Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, Quirk JM, et al. Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med. 1973;289:9–14
  16. Desnick RJ, Dean KJ, Grabowski G, Bishop DF, Sweeley CC. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci U S A. 1979;76:5326–5330
  17. Mapes CA, Anderson RL, Sweeley CC, Desnick RJ, Krivit W. Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science. 1970;169:987–989
  18. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J. 2008;3:90–97
  19. Kornreich R, Desnick RJ, Bishop DF. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res. 1989;17:3301–3302
  20. Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest. 1989;83:1390–1399
  21. Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med. 2000;48:227–235
  22. Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, et al. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med. 1999;5:806–811
  23. Lyon MF. Some milestones in the history of X-chromosome inactivation. Annu Rev Genet. 1992;26:16–28
  24. Laney DA, Fernhoff PM. Diagnosis of Fabry disease via analysis of family history. J Genet Couns. 2008 Jan 3;[Epub ahead of print]
  25. Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr. 2004;144:20–26
  26. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke. 2001;32:1559–1562
  27. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229–233
  28. Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol. 2002;19:575–586
  29. Low M, Nicholls K, Tubridy N, Hand P, Velakoulis D, Kiers L, et al. Neurology of Fabry disease. Intern Med J. 2007;37:436–447
  30. Moller AT, Jensen TS. Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol. 2007;3:95–106
  31. Schiffmann R, Scott LJ. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr. 2002;91:48–52
  32. Toyooka K, Said G. Nerve biopsy findings in hemizygous and heterozygous patients with Fabry's disease. J Neurol. 1997;244:464–468
  33. Kolodny E, Pastores G. Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol. 2002;13:150–153
  34. Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, et al. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci. 1998;18:109–117
  35. Tabata H, Yamakage A, Yamazaki S. Hair abnormality of Fabry disease. Int J Dermatol. 1996;35:576–578
  36. Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry's disease. Am J Gastroenterol. 1981;76:246–251
  37. Sessa A, Meroni M, Battini G, Maglio A, Brambilla PL, Bertella M, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis. 2001;24:66–70
  38. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62:1933–1946
  39. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease. Z Kardiol. 2002;91:786–795
  40. Linhart A, Magage S, Palecek T, Bultas J. Cardiac involvement in Fabry disease. Acta Paediatr Suppl. 2002;91:15–20
  41. deVeber GA . Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol. 1992;31:409–415
  42. Kaye EM, Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol. 1988;23:505–509
  43. Rosenberg DM, Ferrans VJ, Fulmer JD, Line BR, Barranger JA, Brady RO, et al. Chronic airflow obstruction in Fabry's disease. Am J Med. 1980;68:898–905
  44. Nistal M, Paniagua R, Picazo ML. Testicular and epididymal involvement in Fabry's disease. J Pathol. 1983;141:113–124
  45. Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007 Nov 12;[Epub ahead of print]
  46. Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology. 1982;32:498–502
  47. Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol. 2006;5:791–795
  48. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol. 1996;40:8–17
  49. Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet. 2002;3:10
  50. Morgan SH, Rudge P, Smith SJ, Bronstein AM, Kendall BE, Holly E, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency): investigation of symptomatic and presymptomatic patients. Q J Med. 1990;75:491–507
  51. Marino S, Borsini W, Buchner S, Mortilla M, Stromillo ML, Battaglini M, et al. Diffuse structural and metabolic brain changes in Fabry disease. J Neurol. 2006;253:434–440
  52. Keilmann A. Inner ear function in children with Fabry disease. Acta Paediatr. 2003;92:31–32
  53. Ries M, Kim HJ, Zalewski CK, Mastroianni MA, Moore DF, Brady RO, et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain. 2007;130:143–150
  54. Hegemann S, Hajioff D, Conti G, Beck M, Sunder-Plassmann G, Widmer U, et al. Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest. 2006;36:654–662
  55. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184–192
  56. Mohrenschlager M, Braun-Falco M, Ring J, Abeck D. Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol. 2003;4:189–196
  57. Schiller PI, Itin PH. Angiokeratomas: an update. Dermatology. 1996;193:275–282
  58. Okubo H. Several functional and fluorescein fundus angiographic findings in Fabry's disease. Ophthalmologica. 1988;196:132–136
  59. Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2006;14:14
  60. Hauser AC, Lorenz M, Sunder-Plassmann G. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. J Intern Med. 2004;255:629–636
  61. Franceschetti AT. Fabry disease: ocular manifestations. Birth Defects Orig Artic Ser. 1976;12:195–208
  62. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol. 1979;97:671–676
  63. Andersen MV, Dahl H, Fledelius H, Nielsen NV. Central retinal artery occlusion in a patient with Fabry's disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol. 1994;72:635–638
  64. Abe H, Sakai T, Sawaguchi S, Hasegawa S, Takagi M, Yoshizawa T, et al. Ischemic optic neuropathy in a female carrier with Fabry's disease. Ophthalmologica. 1992;205:83–88
  65. Meroni M, Spisni C, Tazzari S, Di Vito R, Stingone A, Bovan I, et al. Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male. Nephrol Dial Transplant. 1997;12:221–223
  66. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine. 2002;81:122–138
  67. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;15(123):754–762
  68. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008 Jan 9;[Epub ahead of print]
  69. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547–1557
  70. Fabry RADAR 2007: The Fabry Registry Aggregate Data Annual Report.
  71. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int. 2002;61:249–255
  72. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr. 2003;162:767–772
  73. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110:1047–1053
  74. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407–1411
  75. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation. 2003;22(107):1978–1984
  76. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003;108:1299–1301
  77. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69:1216–1221
  78. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J. 2000;139:1101–1108
  79. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479–482
  80. Amann-Vesti BR, Gitzelmann G, Widmer U, Bosshard NU, Steinmann B, Koppensteiner R. Severe lymphatic microangiopathy in Fabry disease. Lymphat Res Biol. 2003;1:185–189
  81. Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G, et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med. 1997;155:1004–1010
  82. Bierer G, Kamangar N, Balfe D, Wilcox WR, Mosenifar Z. Cardiopulmonary exercise testing in Fabry disease. Respiration. 2005;72:504–511
  83. Magage S, Lubanda JC, Susa Z, Bultas J, Karetova D, Dobrovolny R, et al. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis. 2007;30:790–799
  84. Hoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5:1447–1453
  85. Manger B, Mengel E, Schaefer RM. Rheumatologic aspects of lysosomal storage diseases. Clin Rheumatol. 2007;26:335–341
  86. Cox-Brinkman J, Vedder A, Hollak C, Richfield L, Mehta A, Orteu K, et al. Three-dimensional face shape in Fabry disease. Eur J Hum Genet. 2007;15:535–542
  87. Ries M, Moore DF, Robinson CJ, Tifft CJ, Rosenbaum KN, Brady RO, et al. Quantitative dysmorphology assessment in Fabry disease. Genet Med. 2006;8:96–101
  88. Lien YH, Lai LW. Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease. Am J Orthop. 2005;34:192–194
  89. Germain DP, Benistan K, Boutouyrie P, Mutschler C. Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet. 2005;68:93–95
  90. Mersebach H, Johansson JO, Rasmussen AK, Bengtsson BA, Rosenberg K, Hasholt L, et al. Osteopenia: a common aspect of Fabry disease: Predictors of bone mineral density. Genet Med. 2007;9:812–818
  91. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539–548
  92. Grewal RP. Psychiatric disorders in patients with Fabry's disease. Int J Psychiatry Med. 1993;23:307–312
  93. Sadek J, Shellhaas R, Camfield CS, Camfield PR, Burley J. Psychiatric findings in four female carriers of Fabry disease. Psychiatr Genet. 2004;14:199–201
  94. Tsutsumi O, Sato M, Sato K, Mizuno M, Sakamoto S. Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry's disease. Asia Oceania J Obstet Gynaecol. 1985;11:39–45
  95. Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis. 2006;29:106–111
  96. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95:86–92
  97. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science. 1970;167:1268–1269
  98. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308:195–196
  99. Skoog WA, Beck WS. Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood. 1956;11:436–454
  100. Coelho JC, Giugliani R. Fibroblasts of skin fragments as a tool for the investigation of genetic diseases: technical recommendations. Gen Mol Biol. 2000;23:269–271
  101. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338–346
  102. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta. 2005;353:201–203
  103. Kusiak JW, Quirk JM, Brady RO. Purification and properties of the two major isozymes of alpha-galactosidase from human placenta. J Biol Chem. 1978;253:184–190
  104. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–293
  105. Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab. 2007 Nov 16;[Epub ahead of print]
  106. Desnick RJ, Bernstein HS, Astrin KH, Bishop DF. Fabry disease: molecular diagnosis of hemizygotes and heterozygotes. Enzyme. 1987;38:54–64
  107. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215
  108. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet. 1993;53:1186–1197
  109. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology. 1992;(24):104–108
  110. Hilz MJ. Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl. 2002;91:38–42
  111. Argoff CE, Barton NW, Brady RO, Ziessman HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun. 1998;19:887–891
  112. Kelly MM, Leigh R, McKenzie R, Kamada D, Ramsdale EH, Hargreave FE. Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease. Thorax. 2000;55:720–721
  113. Shelley ED, Shelley WB, Kurczynski TW. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol. 1995;12:215–219
  114. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol. 2007;18:2609–2617
  115. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711–722
  116. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9–16
  117. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, et al. Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A. 1997;94:2540–2544
  118. Wang A, Ioannou Y, Zeidner K. Fabry disease: generation of a mouse model with alpha-galactosidase A. Am J Hum Genet. 1996;59
  119. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet. 2001;68:14–25
  120. Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol. 2004;122:900–908
  121. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75:65–74
  122. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77–86
  123. Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr, in press.
  124. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology. 2004;62:1066–1072
  125. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab. 2005;85:255–259
  126. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet. 2004;66:158–165
  127. Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 2006;29:112–118
  128. Hollak CE, Vedder AC, Linthorst GE, Aerts JM. Novel therapeutic targets for the treatment of Fabry disease. Expert Opin Ther Targets. 2007;11:821–833

 Please see Author Disclosures section at the end of this article.

PII: S0022-3476(09)00673-8

doi: 10.1016/j.jpeds.2009.07.003

The Journal of Pediatrics
Volume 155, Issue 4, Supplement , Pages S19-S31 , October 2009

Article Tools

* Image Usage & Resolution